Executive Director, Clinical Development

About Sutro Biopharma

sutrobio.com

Sutro Biopharma is a clinical-stage biotechnology company based in South San Francisco that discovers, develops, and manufactures protein therapeutics for cancer and autoimmune diseases. It leverages an integrated cell-free protein synthesis platform, XpressCF, to design and produce modalities including cytokine-based immuno-oncology agents, bispecific antibodies, and antibody–drug conjugates (ADCs). Its lead ADC candidates, STRO-001 (anti‑CD74 for multiple myeloma and non‑Hodgkin lymphoma) and STRO-002 (anti‑folate receptor‑α for ovarian and endometrial cancers), are engineered with site-specific linker–warhead placement to optimize therapeutic index. Sutro focuses on directing potent modalities at clinically validated targets to accelerate translation from discovery through manufacturing.